Memorial Sloan Kettering Cancer Center: Esophageal Neoplasms trials

The registry lists 34 Esophageal Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 6 have results posted.

Phase 1 7Phase 2 20Phase 3 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07818018Phase 1/2
• Registry for Esophageal and Gastroesophageal Junction CancerRecruitingNCT06558786
• A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2
• Retrospective Review of Esophageal Cancer at MSKCCRecruitingNCT05706558
• A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative ResectionTerminatedNCT04510285Phase 2Results posted
• Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.CompletedNCT00590031Phase 2Results posted
• Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT00515411Phase 2Results posted
• Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and CisplatinCompletedNCT00397904Phase 2Results posted
• Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal AdenocarcinomaCompletedNCT00390416Phase 2Results posted
• Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal CancerCompletedNCT00354679Phase 2Results posted
• A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
• A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
• Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR ImagingActive, not recruitingNCT04400292Not applicable
• A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT04161781
• A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal CancerCompletedNCT02027948Not applicable
• Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal CancerCompletedNCT01558648
• Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally InvasiveCompletedNCT01262040Not applicable
• Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal CancerCompletedNCT00601692Phase 1
• Quality Of Life Outcomes Following Treatment for Esophageal CancerCompletedNCT00598117
• Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal TractActive, not recruitingNCT00582647
• Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT00072332Phase 1
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the EsophagusCompletedNCT00030862Phase 2
• BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With ChemotherapyCompletedNCT00017056Phase 2
• PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the EsophagusCompletedNCT00016900Phase 2
• Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous PaclitaxelCompletedNCT00006245Phase 2
• Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach CancerCompletedNCT00006038Phase 2
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal CancerCompletedNCT00005638Phase 1
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach CancerCompletedNCT00005599Phase 2
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal CancerCompletedNCT00003427Phase 1
• Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1/2
• Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the EsophagusCompletedNCT00003087Phase 2
• Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric CancerCompletedNCT00003055Phase 2
• PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by SurgeryCompletedNCT00002930Phase 2/3
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusCompletedNCT00002711Phase 1